Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
ICUI's Cash-to-Debt is ranked higher than
96% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.55 vs. ICUI: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ICUI' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.75  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.75
ICUI's Equity-to-Asset is ranked higher than
76% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. ICUI: 0.75 )
Ranked among companies with meaningful Equity-to-Asset only.
ICUI' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.44  Med: 0.92 Max: 0.96
Current: 0.75
0.44
0.96
Piotroski F-Score: 4
Altman Z-Score: 7.60
Beneish M-Score: -1.24
WACC vs ROIC
5.86%
-5.35%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -2.16
ICUI's Operating Margin % is ranked higher than
54% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.15 vs. ICUI: -2.16 )
Ranked among companies with meaningful Operating Margin % only.
ICUI' s Operating Margin % Range Over the Past 10 Years
Min: -2.16  Med: 16.7 Max: 21.86
Current: -2.16
-2.16
21.86
Net Margin % 6.10
ICUI's Net Margin % is ranked higher than
86% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. ICUI: 6.10 )
Ranked among companies with meaningful Net Margin % only.
ICUI' s Net Margin % Range Over the Past 10 Years
Min: 6.1  Med: 12.58 Max: 16.63
Current: 6.1
6.1
16.63
ROE % 5.63
ICUI's ROE % is ranked higher than
73% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.37 vs. ICUI: 5.63 )
Ranked among companies with meaningful ROE % only.
ICUI' s ROE % Range Over the Past 10 Years
Min: 5.41  Med: 10.33 Max: 15.02
Current: 5.63
5.41
15.02
ROA % 4.70
ICUI's ROA % is ranked higher than
85% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. ICUI: 4.70 )
Ranked among companies with meaningful ROA % only.
ICUI' s ROA % Range Over the Past 10 Years
Min: 4.7  Med: 9.36 Max: 13.27
Current: 4.7
4.7
13.27
ROC (Joel Greenblatt) % -4.27
ICUI's ROC (Joel Greenblatt) % is ranked higher than
53% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.96 vs. ICUI: -4.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ICUI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4.27  Med: 31.56 Max: 50.5
Current: -4.27
-4.27
50.5
3-Year Revenue Growth Rate 2.30
ICUI's 3-Year Revenue Growth Rate is ranked lower than
58% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.80 vs. ICUI: 2.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ICUI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -2.5  Med: 17.9 Max: 34.6
Current: 2.3
-2.5
34.6
3-Year EBITDA Growth Rate 8.10
ICUI's 3-Year EBITDA Growth Rate is ranked higher than
58% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. ICUI: 8.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ICUI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -19.8  Med: 9.9 Max: 35
Current: 8.1
-19.8
35
3-Year EPS without NRI Growth Rate 11.40
ICUI's 3-Year EPS without NRI Growth Rate is ranked higher than
66% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. ICUI: 11.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ICUI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -32.2  Med: 12.7 Max: 66
Current: 11.4
-32.2
66
GuruFocus has detected 2 Warning Signs with ICU Medical Inc $ICUI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ICUI's 30-Y Financials

Financials (Next Earnings Date: 2017-11-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ICUI Guru Trades in Q3 2016

Joel Greenblatt 55,374 sh (+33.34%)
Paul Tudor Jones 4,251 sh (+13.15%)
Mario Gabelli 70,500 sh (unchged)
Ken Fisher 31,000 sh (unchged)
Jim Simons 739,000 sh (-6.82%)
» More
Q4 2016

ICUI Guru Trades in Q4 2016

Jim Simons 739,700 sh (+0.09%)
Ken Fisher 31,000 sh (unchged)
Paul Tudor Jones Sold Out
Mario Gabelli 70,400 sh (-0.14%)
Joel Greenblatt 32,098 sh (-42.03%)
» More
Q1 2017

ICUI Guru Trades in Q1 2017

Chuck Royce 37,400 sh (New)
Ken Fisher 31,000 sh (unchged)
Mario Gabelli 68,600 sh (-2.56%)
Jim Simons 696,849 sh (-5.79%)
Joel Greenblatt 20,883 sh (-34.94%)
» More
Q2 2017

ICUI Guru Trades in Q2 2017

Caxton Associates 2,500 sh (New)
Ken Fisher 63,000 sh (+103.23%)
Chuck Royce 47,400 sh (+26.74%)
Mario Gabelli 67,800 sh (-1.17%)
Jim Simons 588,300 sh (-15.58%)
Joel Greenblatt 5,259 sh (-74.82%)
» More
» Details

Insider Trades

Latest Guru Trades with ICUI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2017-06-30 Reduce -1.17%$146.3 - $174.75 $ 181.7514%67,800
Ken Fisher 2017-06-30 Add 103.23%0.01%$146.3 - $174.75 $ 181.7514%63,000
Joel Greenblatt 2017-06-30 Reduce -74.82%0.03%$146.3 - $174.75 $ 181.7514%5,259
Mario Gabelli 2017-03-31 Reduce -2.56%$131.88 - $158.3 $ 181.7524%68,600
Joel Greenblatt 2017-03-31 Reduce -34.94%0.02%$131.88 - $158.3 $ 181.7524%20,883
Mario Gabelli 2016-12-31 Reduce -0.14%$125.7 - $151.75 $ 181.7526%70,400
Joel Greenblatt 2016-12-31 Reduce -42.03%0.04%$125.7 - $151.75 $ 181.7526%32,098
Joel Greenblatt 2016-09-30 Add 33.34%0.02%$111.5 - $127.7 $ 181.7551%55,374
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NYSE:CMD, NAS:PODD, NYSE:HAE, NYSE:HRC, NYSE:HYH, NAS:MMSI, NAS:NXTM, NAS:OSUR, NAS:ATRI, NAS:IRTC, NYSE:GKOS, NAS:LMNX, NAS:LMAT, NAS:ATRC, NAS:ANGO, NAS:STAA, NAS:ATRS, NAS:ENTL, NAS:ELGX, NAS:SIEN » details
Traded in other countries:IC7.Germany,
Headquarter Location:USA
ICU Medical Inc is engaged in the development, manufacture and sale of medical devices used in infusion therapy, oncology and critical care applications. Its products include needlefree connectors, nanoclave, chemoclock, chemoclave, and among others.

ICU Medical Inc is a Delaware Corporation founded in 1984 and its initial public offering was in 1992. The Company is engaged in the development, manufacture and sale of medical devices used in infusion therapy, oncology and critical care applications. Its products improve patient outcomes by helping to prevent bloodstream infections and protect healthcare workers and patients from exposure to infectious diseases or hazardous drugs and monitoring continuous cardiac output of critical care patients. The Company's complete product line includes custom infusion systems, closed delivery systems for hazardous drugs, needle free infusion connectors, catheters and cardiac monitoring systems. Its products are categorized into three main product lines: Infusion Therapy, Critical Care and Oncology. I.V. therapy lines, used in hospitals and ambulatory clinics, consist of a tube running from a bottle or plastic bag containing an I.V. solution to a catheter inserted in a patient's vein. The tube typically has several injection ports or Y-sites (conventionally, entry tubes covered by rubber caps) to which a secondary I.V. line can be connected to permit constant intravenous administration of medications, fluids and nutrients, and to allow instantaneous intravenous administration of emergency medication. Critical care products are used to monitor vital signs as well as specific physiological functions of key organ systems and Oncology: Oncology products are used to prepare and deliver hazardous medications such as those used in chemotherapy which, if released, can have harmful effects to the healthcare worker and environment. Manufacturing of its products involves injection molding of plastic and silicone parts, manual and automated assembly of the molded plastic parts, needles and other components, quality control inspection, packaging and sterilization. The Company currently sells all of its products to I.V. product manufacturers, independent distributors and direct sales to the end user. It competes with other manufacturers of closed system transfer devices for the safe handling of oncology drugs, notably Becton Dickinson, CareFusion and B Braun. The Company's products are subject to clearance by the United States Food and Drug Administration ("FDA") under a number of statutes including the Food Drug and Cosmetics Act ("FDC Act").

Top Ranked Articles about ICU Medical Inc

ICU Medical, Inc. to Participate at the Morgan Stanley 15th Annual Global Healthcare Conference
ICU Medical Issues a Voluntary Nationwide Recall of One Lot of 0.9% Sodium Chloride Injection Due to the Presence of Particulate Matter
ICU Medical, Inc. Announces Time of Second Quarter 2017 Earnings Call
NanoString Appoints Elisha W. Finney to Board of Directors
ICU Medical, Inc. Announces Time of First Quarter 2017 Earnings Call
Lifshitz & Miller LLP Announces Investigation of Amyris, Inc., Commvault Systems, Inc., ICU Medical, Inc., Incyte Corporation, MOCON, Inc., Ocwen Financial Corporation and ThereapeuticsMD, Inc.
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of ICU Medical, Inc. (ICUI)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICU Medical, Inc. -- ICUI
ICU Medical, Inc. to Present at the 29th Annual ROTH Conference

SAN CLEMENTE, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy, oncology and critical care applications, today announced that Company management will present at the 29th Annual ROTH Conference, held on March 12-15, 2017 at the Ritz-Carlton Hotel in Laguna Niguel, CA.
ICU Medical’s presentation will take place on Monday, March 13 at 9:00 AM Pacific Time. The presentation will be webcast live and can be accessed by going to the Company's website at http://www.icumed.com, clicking on the Investors tab and clicking on the Event Calendar tab. The webcast will also be available by replay. About ICU Medical, Inc. ICU Medical, Inc. (NASDAQ:ICUI) is one of the world’s leading pure-play infusion therapy companies with global operations and a wide-ranging product portfolio that includes IV solutions, IV smart pumps, dedicated and non-dedicated IV sets and needlefree connectors, along with pain management and safety software technology designed to help meet clinical, safety and workflow goals. In addition, the company manufactures automated pharmacy IV compounding systems with workflow technology, closed systems transfer devices for hazardous IV drugs, and cardiac monitoring systems to optimize patient fluid levels. ICU Medical is headquartered in San Clemente, California. On February 3, 2017, ICU Medical completed the acquisition of the Hospira Infusion Systems business from Pfizer. More information about ICU Medical, Inc. can be found at www.icumed.com.
Contact:

ICU Medical, Inc.
Scott Lamb, Chief Financial Officer
(949) 366-2183

ICR, Inc.
John Mills, Partner
(646) 277-1254


Read more...

Ratios

vs
industry
vs
history
PE Ratio 69.62
ICUI's PE Ratio is ranked lower than
52% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.55 vs. ICUI: 69.62 )
Ranked among companies with meaningful PE Ratio only.
ICUI' s PE Ratio Range Over the Past 10 Years
Min: 13.76  Med: 23.35 Max: 70.3
Current: 69.62
13.76
70.3
Forward PE Ratio 30.03
ICUI's Forward PE Ratio is ranked lower than
92% of the 38 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.25 vs. ICUI: 30.03 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 69.62
ICUI's PE Ratio without NRI is ranked lower than
52% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.55 vs. ICUI: 69.62 )
Ranked among companies with meaningful PE Ratio without NRI only.
ICUI' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.78  Med: 23.35 Max: 70.3
Current: 69.62
13.78
70.3
Price-to-Owner-Earnings 129.60
ICUI's Price-to-Owner-Earnings is ranked lower than
90% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.16 vs. ICUI: 129.60 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ICUI' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.74  Med: 23.83 Max: 144.79
Current: 129.6
10.74
144.79
PB Ratio 3.23
ICUI's PB Ratio is ranked higher than
55% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.29 vs. ICUI: 3.23 )
Ranked among companies with meaningful PB Ratio only.
ICUI' s PB Ratio Range Over the Past 10 Years
Min: 1.4  Med: 2.19 Max: 3.77
Current: 3.23
1.4
3.77
PS Ratio 4.50
ICUI's PS Ratio is ranked lower than
70% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.24 vs. ICUI: 4.50 )
Ranked among companies with meaningful PS Ratio only.
ICUI' s PS Ratio Range Over the Past 10 Years
Min: 1.73  Med: 2.92 Max: 6.91
Current: 4.5
1.73
6.91
Price-to-Operating-Cash-Flow 145.75
ICUI's Price-to-Operating-Cash-Flow is ranked lower than
99% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.25 vs. ICUI: 145.75 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ICUI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.24  Med: 15.05 Max: 590.11
Current: 145.75
9.24
590.11
EV-to-EBIT -174.66
ICUI's EV-to-EBIT is ranked lower than
94% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.41 vs. ICUI: -174.66 )
Ranked among companies with meaningful EV-to-EBIT only.
ICUI' s EV-to-EBIT Range Over the Past 10 Years
Min: -176.46  Med: 12.6 Max: 69.5
Current: -174.66
-176.46
69.5
EV-to-EBITDA 170.36
ICUI's EV-to-EBITDA is ranked lower than
89% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.62 vs. ICUI: 170.36 )
Ranked among companies with meaningful EV-to-EBITDA only.
ICUI' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.4  Med: 9.05 Max: 172.1
Current: 170.36
5.4
172.1
EV-to-Revenue 4.39
ICUI's EV-to-Revenue is ranked lower than
67% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.43 vs. ICUI: 4.39 )
Ranked among companies with meaningful EV-to-Revenue only.
ICUI' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.2  Med: 2.2 Max: 5.9
Current: 4.39
1.2
5.9
Shiller PE Ratio 70.91
ICUI's Shiller PE Ratio is ranked lower than
65% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.16 vs. ICUI: 70.91 )
Ranked among companies with meaningful Shiller PE Ratio only.
ICUI' s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.58  Med: 30.5 Max: 71.6
Current: 70.91
17.58
71.6
Current Ratio 4.78
ICUI's Current Ratio is ranked higher than
83% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.69 vs. ICUI: 4.78 )
Ranked among companies with meaningful Current Ratio only.
ICUI' s Current Ratio Range Over the Past 10 Years
Min: 1.5  Med: 10.17 Max: 23.06
Current: 4.78
1.5
23.06
Quick Ratio 2.66
ICUI's Quick Ratio is ranked higher than
67% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. ICUI: 2.66 )
Ranked among companies with meaningful Quick Ratio only.
ICUI' s Quick Ratio Range Over the Past 10 Years
Min: 1.33  Med: 9.36 Max: 22
Current: 2.66
1.33
22
Days Inventory 147.65
ICUI's Days Inventory is ranked lower than
69% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 127.43 vs. ICUI: 147.65 )
Ranked among companies with meaningful Days Inventory only.
ICUI' s Days Inventory Range Over the Past 10 Years
Min: 59.45  Med: 87.75 Max: 147.65
Current: 147.65
59.45
147.65
Days Sales Outstanding 59.06
ICUI's Days Sales Outstanding is ranked lower than
80% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.12 vs. ICUI: 59.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
ICUI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.09  Med: 55.31 Max: 75.32
Current: 59.06
46.09
75.32
Days Payable 29.94
ICUI's Days Payable is ranked lower than
57% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.69 vs. ICUI: 29.94 )
Ranked among companies with meaningful Days Payable only.
ICUI' s Days Payable Range Over the Past 10 Years
Min: 25.03  Med: 27.17 Max: 54.81
Current: 29.94
25.03
54.81

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.70
ICUI's 3-Year Average Share Buyback Ratio is ranked higher than
57% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.00 vs. ICUI: -2.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ICUI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -8.3  Med: -2.6 Max: 2.4
Current: -2.7
-8.3
2.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 6.70
ICUI's Price-to-Net-Current-Asset-Value is ranked higher than
62% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.23 vs. ICUI: 6.70 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ICUI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.72  Med: 3.61 Max: 38.42
Current: 6.7
1.72
38.42
Price-to-Tangible-Book 3.78
ICUI's Price-to-Tangible-Book is ranked higher than
60% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.71 vs. ICUI: 3.78 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ICUI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.31  Med: 2.66 Max: 24.65
Current: 3.78
1.31
24.65
Price-to-Intrinsic-Value-Projected-FCF 2.75
ICUI's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
59% of the 86 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.25 vs. ICUI: 2.75 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ICUI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.79  Med: 1.59 Max: 2.78
Current: 2.75
0.79
2.78
Price-to-Median-PS-Value 1.54
ICUI's Price-to-Median-PS-Value is ranked lower than
87% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. ICUI: 1.54 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ICUI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.59  Med: 1.34 Max: 3.81
Current: 1.54
0.59
3.81
Price-to-Graham-Number 3.42
ICUI's Price-to-Graham-Number is ranked higher than
59% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. ICUI: 3.42 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ICUI' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.91  Med: 1.69 Max: 5.62
Current: 3.42
0.91
5.62
Earnings Yield (Greenblatt) % -0.57
ICUI's Earnings Yield (Greenblatt) % is ranked lower than
58% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.70 vs. ICUI: -0.57 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ICUI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -0.6  Med: 7.7 Max: 14.4
Current: -0.57
-0.6
14.4
Forward Rate of Return (Yacktman) % -5.80
ICUI's Forward Rate of Return (Yacktman) % is ranked lower than
76% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.23 vs. ICUI: -5.80 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ICUI' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -5.8  Med: 12.8 Max: 27.2
Current: -5.8
-5.8
27.2

More Statistics

Revenue (TTM) (Mil) $772.05
EPS (TTM) $ 2.61
Beta0.61
Short Percentage of Float5.95%
52-Week Range $121.76 - 183.65
Shares Outstanding (Mil)19.98

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 1,249 1,331 1,390 1,446
EPS ($) 3.55 6.08 7.65 8.65
EPS without NRI ($) 3.55 6.08 7.65 8.65
EPS Growth Rate
(Future 3Y To 5Y Estimate)
14.50%
Dividends per Share ($)
» More Articles for NAS:ICUI

Headlines

Articles On GuruFocus.com
ICU Medical, Inc. to Participate at the Morgan Stanley 15th Annual Global Healthcare Conference Aug 17 2017 
ICU Medical Issues a Voluntary Nationwide Recall of One Lot of 0.9% Sodium Chloride Injection Due to Jul 28 2017 
ICU Medical, Inc. Announces Time of Second Quarter 2017 Earnings Call Jul 11 2017 
NanoString Appoints Elisha W. Finney to Board of Directors May 10 2017 
ICU Medical, Inc. Announces Time of First Quarter 2017 Earnings Call May 02 2017 
Lifshitz & Miller LLP Announces Investigation of Amyris, Inc., Commvault Systems, Inc., ICU Medical, Apr 28 2017 
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of ICU Medical, Inc. ( Apr 20 2017 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICU Medical, Inc Apr 19 2017 
ICU Medical, Inc. to Present at the 29th Annual ROTH Conference Mar 07 2017 
EW: Potential for Capital Appreciation Oct 03 2014 

More From Other Websites
See what the IHS Markit Score report has to say about ICU Medical Inc. Sep 12 2017
ICU Medical, Inc. breached its 50 day moving average in a Bullish Manner : ICUI-US : August 29, 2017 Aug 29 2017
ICU Medical, Inc. – Value Analysis (NASDAQ:ICUI) : August 23, 2017 Aug 23 2017
ICU Medical, Inc. to Participate at the Morgan Stanley 15th Annual Global Healthcare Conference Aug 17 2017
Corporate News Blog - STAAR Surgical Announces Strategic Cooperation Agreement with Seoul/Busan Eye... Aug 17 2017
Edited Transcript of ICUI earnings conference call or presentation 9-Aug-17 8:30pm GMT Aug 12 2017
ICU Medical, Inc. breached its 50 day moving average in a Bearish Manner : ICUI-US : August 11, 2017 Aug 11 2017
ICU Medical reports 2Q loss Aug 09 2017
ICU Medical, Inc. Announces Second Quarter 2017 Results Aug 09 2017
Investor Network: ICU Medical, Inc. to Host Earnings Call Aug 09 2017
ICU Medical Issues a Voluntary Nationwide Recall of One Lot of 0.9% Sodium Chloride Injection Due to... Jul 28 2017
ETFs with exposure to ICU Medical, Inc. : July 11, 2017 Jul 11 2017
ICU Medical, Inc. Announces Time of Second Quarter 2017 Earnings Call Jul 11 2017
ETFs with exposure to ICU Medical, Inc. : June 30, 2017 Jun 30 2017
ICU Medical, Inc. :ICUI-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Jun 16 2017
Edited Transcript of ICUI earnings conference call or presentation 10-May-17 8:30pm GMT May 16 2017
ICU Medical posts 1Q profit May 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}